Fapilavir completes clinical research and shows good clinical efficacy
On March 17th, the State Council's joint prevention and control mechanism held a press conference on the latest research and development of drug vaccines and testing reagents. Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, introduced that fapilavir has completed clinical studies and shows that Clinical efficacy. In terms of safety, Fapilavir was approved for listing in Japan in 2014, and no obvious adverse reactions have been seen since listing. No clinically significant adverse reactions have been found in the clinical studies of neocoronary pneumonia.